Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 4,760 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Branch II Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors

NCT01450020
View directory record Official record
Conditions
Breast Cancer
Interventions
educational intervention, questionnaire administration, counseling intervention, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

NCT02900976
View directory record Official record
Conditions
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Suspended Phase 2 Interventional

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT06538389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

NCT07226713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pacritinib
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00527124
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions
cediranib maleate, docetaxel, prednisone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 27, 2026, 6:59 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597
View directory record Official record
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

NCT01606579
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions
PRI-724
Drug
Lead sponsor
Prism Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 27, 2026, 6:59 PM EDT
Not yet recruiting Phase 2 Interventional

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

NCT07390968
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00357760
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
VEGF Trap
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
204
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 27, 2026, 6:59 PM EDT
Recruiting Phase 3 Interventional

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
212
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968
View directory record Official record
Conditions
Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Interventions
Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Paclitaxel, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
536
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MK-3475, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 27, 2026, 6:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

NCT03287817
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
AUTO3
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

NCT01641068
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Cognitive Side Effects of Cancer Therapy, Malignant Female Reproductive System Neoplasm
Interventions
Cognitive Intervention, Educational Intervention, Functional Magnetic Resonance Imaging, Memory Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

NCT03857620
View directory record Official record
Conditions
Malignant Neoplasm, Surgical Procedure, Unspecified, Health Care Provider, Carcinoma
Interventions
Best Practice, Informational Intervention, Questionnaire Administration, Informational Intervention with Coaching
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
70 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
44
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Augusta, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 27, 2026, 6:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity in Promoting Smoking Cessation in African Americans

NCT01915810
View directory record Official record
Conditions
Current Smoker, Healthy Subject
Interventions
Exercise Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Tobacco Cessation Counseling
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02965378
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1083
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 27, 2026, 6:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

NCT07407582
View directory record Official record
Conditions
Solid Tumor Malignancies, Testicular Cancer, Head and Neck Cancer, Thoracic Cancer
Interventions
Pedmark® STS
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

NCT01367574
View directory record Official record
Conditions
Bowel Dysfunction
Interventions
SC MNTX
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 27, 2026, 6:59 PM EDT
Not yet recruiting Not applicable Interventional

The Emmetropization Via Accommodation (EVA) - II Study

NCT07838597
View directory record Official record
Conditions
Hyperopia, Farsightedness, Hypermetropia
Interventions
Experimental treatment arm
Combination Product
Lead sponsor
Ohio State University
Other
Eligibility
13 Weeks to 19 Weeks
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 27, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

NCT01414608
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
315
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 27, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

NCT01192815
View directory record Official record
Conditions
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies, gene expression analysis, 3-dimensional conformal radiation therapy, biopsy, pharmacological study, laboratory biomarker analysis, questionnaire administration, enzyme-linked immunosorbent assay, polymorphism analysis
Drug · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 27, 2026, 6:59 PM EDT